Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Regenerex Pharma
Las Vegas, Nevada, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Regenerex Pharma's wound care products, based on its QBx™ platform and incorporating ovine nano-collagen and wound-healing actives, are FDA- and CE-cleared medical devices. In clinical evaluations, 95% of chronic wounds achieved full closure within 90 days, including highly refractory diabetic foot ulcers, venous stasis ulcers, burns, and pressure ulcers[2][3][6][7].
- Therapeutic areas
- EndocrinologyDermatologyCardiovascular
- Modalities
- Medical deviceBiologicSmall molecule
- Industry
- Consumable Medical Devices
02
Partnerships
Holista Colltech Ltd.
Beyond the preview
Go deeper on Regenerex Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regenerex Pharma.